Paul R. Fonteyne

Mr. Paul R.
Fonteyne is an Independent Director at Apnimed, Inc., an Independent Director at Amylyx Pharmaceuticals, Inc., a Chairman at DalCor Pharmaceuticals Canada, Inc. and an Independent Non-Executive Director at Ypsomed Holding AG.
He is on the Board of Directors at Apnimed, Inc., Amylyx Pharmaceuticals, Inc., Ypsomed AG, Ypsomed Holding AG, Allyx Therapeutics, Inc., DalCor Pharma UK Ltd. and Revelar Biotherapeutics, Inc. Mr. Fonteyne was previously employed as an Independent Director by Gelesis Holdings, Inc., an Independent Director by Covetrus, Inc., a Chief Executive Officer by Thyron Pharmaceuticals, Inc., an Independent Director by Apellis Pharmaceuticals, Inc., an Independent Director by AMAG Pharmaceuticals, Inc., a President by Boehringer Ingelheim Vetmedica, Inc., an Independent Director by resTORbio, Inc., a President & Chief Executive Officer by Boehringer Ingelheim Pharmaceuticals, Inc., a Chairman, President, Chief Executive Officer & MD by Boehringer Ingelheim Corp., a Senior VP-Prescription Medicines Marketing by Boehringer Ingelheim GmbH, a Vice President-Sales by Merck & Co., Inc., a Chairman-New England by American Cancer Society, Inc., and a Chairman by National Pharmaceutical Council.
He also served on the board at Gelesis, Inc. and Pharmaceutical Research & Manufacturers of America.
He received his graduate degree from Université Libre de Bruxelles and an MBA from Carnegie Mellon University.